The ideal candidate for off label prescription is one that is proven safe in humans and has shown efficacy across a range of cancer types and in combination therapy.
If the data proves efficacy in the 10 bile duct patients shareholders will be the second happiest people to have engaged with Imugene.
My opinion only DYOR
Fact Finder
The ideal candidate for off label prescription is one that is...
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.9¢ |
Change
0.001(2.08%) |
Mkt cap ! $364.4M | |||
| Open | High | Low | Value | Volume |
| 4.8¢ | 4.9¢ | 4.8¢ | $179.8K | 3.692M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 62 | 8124186 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 3070575 | 9 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |